(redirected from Osteoprotegerin)
Also found in: Medical, Encyclopedia, Wikipedia.
ÖPGÖsterreichische Physikalische Gesellschaft (German: Austrian Physical Society)
References in periodicals archive ?
Bonnelye, "Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption," Medscape Women's Health, vol.
Osteoprotegerin, also known as osteoprotegrin, (OPG) is a basic glycoprotein that is found either as a 60 kDa monomer or as a 120 kDa dimer.
Simonet, "Generalized degenerative joint disease in osteoprotegerin (Opg) null mutant mice," Veterinary Pathology, vol.
Ernestam et al., "Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis," Arthritis and Rheumatism, vol.
Kitazawa, "Dexamethasone promotes osteoclastogenesis by inhibiting osteoprotegerin through multiple levels," Journal of Cellular Biochemistry, vol.
Furthermore, the mRNA levels for osteoprotegerin and RUNX2 in the bone marrows from irradiated mice were significantly lower than those in the non-irradiated mice (both P-values < 0.05; Fig.
First, it causes osteoblasts to secrete osteoprotegerin rather than RANKL, causing reduced activation of osteoclasts.
Osteoprotegerin (OPG), the receptor activator of nuclear factor-[kappa]B (RANK), and RANK ligand (RANKL) comprise a system of proteins that play a key role in regulating bone remodeling and are well known as targets for developing therapeutics to treat osteoporosis.
The investigators observed elevated levels of most bone formation markers (bone alkaline phosphatase, osteocalcin, and osteoprotegerin) and bone absorption markers (urinary calcium, osteopontin, and RANKL) [15].
Tumor cells expressing jagged-1 may indirectly alter the expression of OB-derived RANKL and osteoprotegerin (OPG) [27].
The first is receptor activator of NF-kB ligand (RANKL) [2], also called osteoclast differentiation factor (ODF) [3], osteoprotegerin ligand (OPGL) [4], or TNF-related activation-induced cytokine (TRANCE) [5].
Lorenzo, "Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation," Endocrinology, vol.